Defining the optimal murine models to investigate immune checkpoint blockers and their combination with other immunotherapies
Open Access
- 23 February 2016
- journal article
- review article
- Published by Elsevier BV in Annals of Oncology
- Vol. 27 (7), 1190-1198
- https://doi.org/10.1093/annonc/mdw041
Abstract
The recent success of checkpoint blockers to treat cancer has demonstrated that the immune system is a critical player in the war against cancer. Historically, anticancer therapeutics have been tested in syngeneic mouse models (with a fully murine immune system) or in immunodeficient mice that allow the engraftment of human xenografts. Animal models with functioning human immune systems are critically needed to more accurately recapitulate the complexity of the human tumor microenvironment. Such models are integral to better predict tumor responses to both immunomodulatory agents and directly antineoplastic therapies. In this regard, the development of humanized models is a promising, novel strategy that offers the possibility of testing checkpoint blockers' capacity and their combination with other antitumor drugs. In this review, we discuss the strengths and weaknesses of the available animal models regarding their capacity to evaluate checkpoint blockers and checkpoint blocker-based combination immunotherapy.Keywords
Funding Information
- Sociedad Española de Oncología Médica
- MICINN (SAF2011-22831, SAF2014-52361-R)
- Sociedad Española de Oncología Médica
- MICINN (SAF2011-22831, SAF2014-52361-R)
This publication has 64 references indexed in Scilit:
- Bi-specific TCR-anti CD3 redirected T-cell targeting of NY-ESO-1- and LAGE-1-positive tumorsCancer Immunology, Immunotherapy, 2012
- A Programmable Dual-RNA–Guided DNA Endonuclease in Adaptive Bacterial ImmunityScience, 2012
- Expression of tumour-specific antigens underlies cancer immunoeditingNature, 2012
- Redefining the relevance of established cancer cell lines to the study of mechanisms of clinical anti-cancer drug resistanceProceedings of the National Academy of Sciences of the United States of America, 2011
- Expression of human cytokines dramatically improves reconstitution of specific human-blood lineage cells in humanized miceProceedings of the National Academy of Sciences of the United States of America, 2009
- Conditional mouse lung cancer models using adenoviral or lentiviral delivery of Cre recombinaseNature Protocols, 2009
- Human peripheral blood leucocyte non-obese diabetic-severe combined immunodeficiency interleukin-2 receptor gamma chain gene mouse model of xenogeneic graft-versus-host-like disease and the role of host major histocompatibility complexClinical and Experimental Immunology, 2009
- IL-15 trans-presentation promotes human NK cell development and differentiation in vivoThe Journal of Experimental Medicine, 2008
- Factors affecting human T cell engraftment, trafficking, and associated xenogeneic graft-vs-host disease in NOD/SCID β2mnull miceExperimental Hematology, 2007
- Comparative biology of mouse versus human cells: modelling human cancer in miceNature Reviews Cancer, 2003